MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near

Summary

MLTX stock is experiencing its worst week since the prior fall as the FDA filing date for the company's skin disease drug candidate approaches. The stock decline suggests investor concerns ahead of the regulatory submission.